Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (141-150 of 336) with videos related to

Pageof 34
Sort By:
BMJ Supportive & Palliative Care|September 4, 2023
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictorsAlessandro Leonetti, Marianna Peroni, Virginia Agnetti, et al.
Future Oncology (London, England)|January 10, 2015
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Sebastiano Buti, Chiara Ciccarese, Daniele Zanoni, et al.
Frontiers in Immunology|May 1, 2026
An agent-based learning model integrating sex differences in renal cell carcinomaEmanuela Merelli, Tarek Taha, Marco Caputo, et al.
Frontiers in Oncology|April 1, 2025
Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case reportIlaria Gandolfini, Martina Manini, Giuseppe Daniele Benigno, et al.
Immunotherapy|July 17, 2018
Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumabMelissa Bersanelli, Letizia Gnetti, Cinzia Azzoni, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 7, 2023
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancerMalvina Cremante, Silvia Puglisi, Annalice Gandini, et al.
Immunotherapy|January 4, 2023
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case reportVeronica Murianni, Luigi Cerbone, Pasquale Rescigno, et al.
Frontiers in Oncology|December 13, 2021
Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)Marco Maruzzo, Elena Verzoni, Maria Giuseppa Vitale, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLCGiulia Mazzaschi, Francesco Facchinetti, Gabriele Missale, et al.
Biochemical Pharmacology|June 29, 2024
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatmentsClaudia Fumarola, Silvia La Monica, Mara Bonelli, et al.
Pageof 34

Showing results (141-150 of 336) with videos related to

Sort By:
Pageof 34
BMJ Supportive & Palliative Care|September 4, 2023
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictorsAlessandro Leonetti, Marianna Peroni, Virginia Agnetti, et al.
Future Oncology (London, England)|January 10, 2015
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Sebastiano Buti, Chiara Ciccarese, Daniele Zanoni, et al.
Frontiers in Immunology|May 1, 2026
An agent-based learning model integrating sex differences in renal cell carcinomaEmanuela Merelli, Tarek Taha, Marco Caputo, et al.
Frontiers in Oncology|April 1, 2025
Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case reportIlaria Gandolfini, Martina Manini, Giuseppe Daniele Benigno, et al.
Immunotherapy|July 17, 2018
Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumabMelissa Bersanelli, Letizia Gnetti, Cinzia Azzoni, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|June 7, 2023
Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancerMalvina Cremante, Silvia Puglisi, Annalice Gandini, et al.
Immunotherapy|January 4, 2023
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case reportVeronica Murianni, Luigi Cerbone, Pasquale Rescigno, et al.
Frontiers in Oncology|December 13, 2021
Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)Marco Maruzzo, Elena Verzoni, Maria Giuseppa Vitale, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLCGiulia Mazzaschi, Francesco Facchinetti, Gabriele Missale, et al.
Biochemical Pharmacology|June 29, 2024
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatmentsClaudia Fumarola, Silvia La Monica, Mara Bonelli, et al.
Pageof 34